For everyone, our monthly reports are free. These long-reads are meant to educate and to share our perspective on an indication, drug class, or technology/platform in an accessible way.

For subscribers-only, we will release biweekly deep-dive due diligence reports for one specific company, along with other recurring biotech equity research notes and posts.

Why subscribe?

We have a deep passion for biotech due diligence. What started out as a pastime since 2015 is now a rigorous screening process for each company’s scientific potential, clinical results, strategy & management, and financial health. We wish to let our research and track record speak for itself.

To help you get the bigger picture behind some of our biotech picks, we simplify the technical scientific concepts behind each company’s drug(s) and explain the ‘so-what’ for both patients and the greater market. We also share insights and observations that aren’t found in conventional equity reports.

While we’ve had our successes investing in tech, bitcoin, and passively in ETFs, we’ve found much more meaning, returns, and excitement in biotech. We believe that we are still in the early stages of a major innovation breakout in biotech.